SOUTH SAN FRANCISCO, Calif.,
Nov. 9, 2021 /PRNewswire/
-- Rigel Pharmaceuticals, Inc. (Nasdaq:RIGL) today
announced that Dean Schorno, the
company's chief financial officer, will participate in the
following virtual investor conferences in November:
Jefferies Virtual London Healthcare Conference (November 18-19, 2021)
- Dean Schorno will present a
company overview, which will be available for on-demand viewing
starting on Thursday, November 18, at
8:00 a.m. GMT / 3:00 a.m. ET
Piper Sandler 33rd
Annual Virtual Healthcare Conference (November 29-December 2, 2021)
- Dean Schorno will participate in
a fireside chat which will be available to conference attendees
starting on Monday, November 22, at
10:00 a.m. ET
To access the webcast of the Jefferies London Healthcare
Conference presentation, go to the Investor Relations section of
the company's website at www.rigel.com.
About Rigel (www.rigel.com)
Rigel Pharmaceuticals,
Inc., is a biotechnology company dedicated to discovering,
developing and providing novel small molecule drugs that
significantly improve the lives of patients with hematologic
disorders, cancer and rare immune diseases. Rigel's pioneering
research focuses on signaling pathways that are critical to disease
mechanisms. The company's first FDA approved product is TAVALISSE®
(fostamatinib disodium hexahydrate) tablets, the only oral spleen
tyrosine kinase (SYK) inhibitor for the treatment of adult patients
with chronic immune thrombocytopenia who have had an insufficient
response to a previous treatment. The product is also commercially
available in Europe, the
United Kingdom (TAVLESSE) and
Canada (TAVALISSE) for the
treatment of chronic immune thrombocytopenia in adult patients.
Fostamatinib is currently being studied in a Phase 3 clinical
trial (NCT03764618) for the treatment of warm autoimmune hemolytic
anemia (wAIHA)1; a Phase 3 clinical trial (NCT04629703)
for the treatment of hospitalized high-risk patients with
COVID-191; an NIH/NHLBI-sponsored Phase 3 clinical trial
(ACTIV-4 Host Tissue Trial, NCT04924660) for the treatment of
COVID-19 in hospitalized patients, and a Phase 2 clinical trial
(NCT04581954) for the treatment of COVID-19 being conducted by
Imperial College London.
Rigel's other clinical programs include its interleukin
receptor-associated kinase (IRAK) inhibitor program, and a
receptor-interacting serine/threonine-protein kinase (RIP1)
inhibitor program in clinical development with partner Eli Lilly
and Company. In addition, Rigel has product candidates in
development with partners AstraZeneca, BerGenBio ASA, and Daiichi
Sankyo.
For further information, visit www.rigel.com or follow us on
Twitter or LinkedIn.
Please see www.TAVALISSE.com for the full Prescribing
Information.
1 The product for this use or indication is
investigational and has not been proven safe or effective by any
regulatory authority.
Investor Contact:
Jodi Sievers
Rigel Pharmaceuticals, Inc.
Phone: 650.624.1232
Email: ir@rigel.com
View original content to download
multimedia:https://www.prnewswire.com/news-releases/rigel-to-participate-in-two-upcoming-investor-conferences-301419369.html
SOURCE Rigel Pharmaceuticals, Inc.